Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools Spyre Therapeutics focuses on antibody therapies for inflammatory bowel disease, advancing a pipeline aimed at gastrointestinal health.
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down This ophthalmic biopharma firm develops sustained drug delivery therapies for eye diseases, targeting both U.S. and global markets.
VR Adviser Adds Over 1 Million Savara Shares This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials.
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing.
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market.
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs.
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials.
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst This clinical-stage biotech develops therapies targeting hematologic disorders, with a pipeline centered on red blood cell biology.
The Great Rotation: Small-Cap Stocks Slay the Giants as Market Breadth Hits Record Highs NEW YORK — After years of living in the shadow of trillion-dollar tech titans, the "little guys" of the stock market are finally having their day in the sun. As of February 24, 2026, the financial landscape has undergone a dramatic shift, punctuated by a stunning 5.4% surge in the
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions.
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials.
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector.
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress Praxis Precision Medicines develops therapies for central nervous system disorders, with candidates targeting depression and epilepsy.
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million This clinical-stage biotech develops monoclonal antibody therapies targeting chronic inflammatory and immunological diseases.
The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership In a move that has rewritten the record books of Wall Street, the small-cap-heavy Russell 2000 index recently concluded a historic 15-session winning streak of daily outperformance against the S&P 500. This rally, which reached its zenith on January 22, 2026, represents the longest period of small-cap dominance since
What Investors Should Know About a $1.5 Million Apogee Insider Sale Amid a 60% Stock Rally This clinical-stage biotech focused on long-acting antibody therapies reported a notable insider sale amid ongoing pipeline development.
Apogee Therapeutics Chief Medical Officer Sells $817,500 Worth of Shares After Monster December Rally This clinical-stage biotech focused on immunology therapies reported a notable insider sale amid ongoing pipeline development.
Why Apogee Therapeutics Stock Triumphed on Thursday The company aims to raise gross proceeds of roughly $300 million in a new capital-raising effort.
Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out The small biotech company is looking to take on Regeneron and Sanofi's blockbuster, Dupixent.
What's going on in today's after hours session Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.
